leukemia

[Blood Advances] Investigators conducted a Phase II, multicenter, open-label study to evaluate the safety and antileukemic activity of azacitidine monotherapy prior to hematopoietic stem cell transplantation in newly diagnosed juvenile myelomonocytic leukemia patients.

[Leukemia] Scientists used two different single-cell RNA sequencing technologies to analyze the expression of a prednisone-dependent signature, derived from an independent study, in diagnostic bone marrow and peripheral blood biopsies.

[Kronos Bio, Inc.] Kronos Bio, Inc. announced the US FDA has cleared its Investigational New Drug Application for LANRA, allowing the company to proceed with a Phase I/II clinical trial of LANRA in patients with relapsed or refractory FLT3-mutated AML in combination with gilteritinib.

[Cancer Discovery] Scientists demonstrated that an oncogenic mutant form of NPM1 (NPM1c) impaired mitochondrial function. NPM1c also hampered formation of PML nuclear bodies, which are regulators of mitochondrial fitness and key senescence effectors.

[Magenta Therapeutics, Inc.] Magenta Therapeutics, Inc. announced that it has received a clinical hold letter from the US FDA related to its Investigational New Drug Application filed in June 2021 to initiate a Phase I/II clinical trial of MGTA-117 in patients with acute myeloid leukemia and myelodysplastic syndrome.

[Nature Medicine] Ten of 16 patients with large B cell lymphoma with progressive disease after CAR19 treatment had absent or low CD19.